Evonetix

Evonetix has developed a proprietary benchtop gene synthesis platform that uses semiconductor-controlled silicon chips to enable high-fidelity, parallelized production of long DNA sequences. The system integrates assembly and error correction steps on-chip to deliver accurate gene-length DNA rapidly. This approach aims to decentralize and accelerate synthetic biology research across healthcare, agriculture, manufacturing, and sustainability sectors by putting advanced gene foundries into individual labs rather than relying on centralized service providers. The company’s technology could facilitate breakthroughs in personalized medicine (e.g., cell engineering for cancer), crop improvement, novel biomaterials development, and more. As of May 2024 the product remains pre-commercial but has attracted significant investment.